In the era of targeted therapies and im-munotherapy for cancer, the focus in breast cancer (BC) research has shifted away from classical chemotherapy. Many BC patients, however, still need chemotherapy and thus benefit from the development of new chemotherapeutic agents or regimens. In the past decade, the approval of eribulin and trastuzumab emtansine (T-DM1) have been important advances in this regard. Improved ways of delivery of pacli-taxel, anthracyclines, and vinorelbine have also had a considerable clinical impact. Finally, optimizing the use of well-known drugs, such as carboplatin, capecitabine, or adjuvant chemoimmunotherapy in low-risk early BC, has brought about progress in the field of chemo(immuno)therapy.
展开▼
机译：在癌症靶向治疗和免疫治疗的时代，乳腺癌（BC）研究的重点已经从经典化疗转移。然而，许多 BC 患者仍然需要化疗，因此受益于新的化疗药物或方案的开发。在过去十年中，艾日布林和曲妥珠单抗 emtansine （T-DM1） 的批准是这方面的重要进展。紫杉醇、蒽环类药物和长春瑞滨的给药方式的改进也产生了相当大的临床影响。最后，优化卡铂、卡培他滨等知名药物或辅助化学免疫治疗在低风险早期 BC 中的应用，为化疗（免疫）治疗领域带来了进展。
展开▼
